WT1 126-134 peptide
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies.
For research use only. We do not sell to patients.
- CAS No.: 256952-63-3
- Formula: C52H77N13O12S
- Molecular Weight:1108.31
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 3 weeks) combined with the auxiliary peptide (WT135-52) significantly enhances CTL induction and delays tumor growth induced by mWT1-C1498 cells in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TRAMP-C2 murine prostate cancer cell syngeneic tumor model established in male C57BL/6 mice[1]
-
Dosage:100 μg, emulsified with incomplete Freund’s adjuvant
-
Administration:Intraperitoneal injection (i.p.), once a week for 2 weeks
-
Result:Induced peptide-specific CTL, but was unable to effectively recognize the naturally expressed WT1 protein.
Failed to produce significant anti-tumor effects.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 256952-63-3
-
Appearance Solid
-
Molecular Weight 1108.31
-
Formula C52H77N13O12S
-
Color White to off-white
-
Sequence
Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu
-
Sequence Shortening
RMFPNAPYL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shirakawa T, Kitagawa K. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. Hum Vaccin Immunother. 2018 Jan 2;14(1):159-162. [Content Brief]
[3]. Nakajima H, et al. Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunol Immunother. 2021 Nov;70(11):3323-3335. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
WT1 126-134 peptide Related Classifications
HY-P11084 Related Classifications
Powered by Bioz